Evidence map›Paper›PMID 39945818›Full record

ReviewArchives of toxicology2025

Bridging imaging-based in vitro methods from biomedical research to regulatory toxicology.

Monica Piergiovanni, Milena Mennecozzi, Erio Barale-Thomas, Davide Danovi, Sebastian Dunst, David Egan, Aurora Fassi, Matthew Hartley, Philipp Kainz, Katharina Koch and 14 more

Abstract readReview
In one paragraph

Review in Archives of toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Monica Piergiovanni *European Commission, Joint Research Centre (JRC), Ispra, Italy. monica.piergiovanni@ec.europa.eu.ORCID 0000-0003-4992-2068
Milena Mennecozzi *European Commission, Joint Research Centre (JRC), Ispra, Italy.
Erio Barale-ThomasPreclinical Sciences and Translational Safety, Janssen Pharmaceuticals, Beerse, Belgium.
Davide DanoviDepartment of Basic and Clinical Neuroscience, King's College London, London, UK.ORCID 0000-0003-4119-5337
Sebastian DunstGerman Centre for the Protection of Laboratory Animals (Bf3R), Department Experimental Toxicology and ZEBET, German Federal Institute for Risk Assessment, Berlin, Germany.
David EganCore Life Analytics BV, 57 Kabelweg, 1014 BA, Amsterdam, The Netherlands.
Aurora FassiEuropean Commission, Joint Research Centre (JRC), Ispra, Italy.
Matthew HartleyEuropean Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, UK.
Philipp KainzKOLAIDO GmbH, Altenrhein, Switzerland.
Katharina KochIUF - Leibniz Research Institute for Environmental Medicine, Duesseldorf, Germany.
Sylvia E Le DévédecLeiden Academic Centre for Drug Research (LACDR), Faculty of Science, Leiden University, 2333, Leiden, Netherlands.ORCID 0000-0002-0615-9616
Iris MangasEuropean Food Safety Authority (EFSA), Parma, Italy.
Elena MirandaBioImaging, GSK, Stevenage, SG1 2NY, UK.
Jo NyffelerDepartment of Ecotoxicology, Helmholtz Centre for Environmental Research - UFZ, Leipzig, Germany.
Enrico PesentiCrown Bioscience Inc, 16550 West Bernardo Drive, Building 5, Suite 525, San Diego, CA, 92127, USA.
Fernanda RicciAxxam SpA, Bresso, Italy.
Christopher SchmiedEU-OPENSCREEN ERIC, Campus Berlin-Buch, Robert-Roessle-Str. 10, 13125, Berlin, Germany.
Alexander SchreinerRevvity Health Sciences, Inc, Waltham, MA, USA.
Nadine Stokar-RegenscheitRoche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070, Basel, Switzerland.
Jason R SwedlowDivisions of Computational Biology and Molecular, Cell and Developmental Biology, School of Life Sciences, National Phenotypic Screening Centre, University of Dundee, Dundee, UK.
Virginie UhlmannBioVisionCenter, University of Zürich, Zurich, Switzerland.
Fredrik C WielandLife Science Business Europe, Yokogawa Deutschland GmbH, Ratingen, Germany.
Amy WilsonSafety Sciences, Clinical Pharmacology and Safety Sciences, AstraZeneca, Cambridge, UK.
Maurice WhelanEuropean Commission, Joint Research Centre (JRC), Ispra, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Imaging technologies are being increasingly used in biomedical research and experimental toxicology to gather morphological and functional information from cellular models. There is a concrete opportunity of incorporating imaging-based in vitro methods in international guidelines to respond to regulatory requirements with human relevant data. To translate these methods from R&D to international regulatory acceptance, the community needs to implement test methods under quality management systems, assess inter-laboratory transferability, and demonstrate data reliability and robustness. This article summarises current challenges associated with image acquisition, image analysis, including artificial intelligence, and data management of imaging-based methods, with examples from the developmental neurotoxicity in vitro battery and phenotypic profiling assays. The article includes considerations on specific needs and potential solutions to design and implement future validation and transferability studies.

Indexed as

Biomedical ResearchImage Processing, Computer-AssistedToxicity TestsToxicologyAnimalsArtificial IntelligenceHumansIn Vitro TechniquesReproducibility of Results3RsArtificial intelligenceHigh content imagingImaging-based in vitro methodsRegulatory toxicologyValidation

Identifiers

PMID39945818
PMCPMC11968550

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.